DANIEL HURLEY: Open Payments
NPI 1255739587 · FARMINGTON HILLS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$881 in 46 payments from 23 companies in 2025. Trend: 2023 $609 · 2024 $774 · 2025 $881
Food & beverage: $881
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 4 | $106 |
| Bausch Health US, LLC | 3 | $66 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $56 |
| Novo Nordisk Inc | 3 | $55 |
| GlaxoSmithKline, LLC. | 3 | $51 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $48 |
| Teva Pharmaceuticals USA, Inc. | 2 | $48 |
| PFIZER INC. | 3 | $48 |
| Axsome Therapeutics, Inc. | 2 | $40 |
| Sumitomo Pharma America, Inc. | 2 | $39 |
Products named: INGREZZA, XIFAXAN, TRELEGY ELLIPTA, CAPLYTA, AUSTEDO XR, APLENZIN, Auvelity, GEMTESA.
Industry payments across MI — which companies pay providers there.
